SpringWorks Therapeutics Reports Positive CHMP Opinion for Mirdametinib as Potential First Therapy for NF1-PN in EU

Press/Media: Research

Period	May 23 2025

Media coverage

Title	SpringWorks Therapeutics Reports Positive CHMP Opinion for Mirdametinib as Potential First Therapy for NF1-PN in EU
Media name/outlet	Nasdaq
Country/Territory	United States
Date	5/23/25
URL	https://www.nasdaq.com/articles/springworks-therapeutics-reports-positive-chmp-opinion-mirdametinib-potential-first
Persons	Michael Schmidt